

Index

A

Abdominal and pelvic traumas, 6–7
Abdominal bleeding, 5, 6
Abdominal infections, 168
Absorbed dose, 214, 215, 217–219
Acute appendicitis, 6
Acute bleeding, 188
Acute cholecystitis, 6
Acute pulmonary embolism, 196
Adrenal gland, 52, 56, 63, 64, 82–83
Anti-granulocyte antibodies, 170
Artifacts, 10–13
Astrocytomas, 122, 124, 125
Attenuation correction, 10, 12, 13

B

Biliary atresia, 6
Biliary colic, 6
Biological target volume (BTV), 214, 221–223
Bleeding, 4–7
Blue dye, 152
Bone fracture, 6
Bone pain, 6
Bone scintigraphy, 6, 106, 107, 114
Brain death, 5–7
Brain tumors, 216, 221
Breast carcinoma, 152–154

C

Carcinoid tumors, 18, 21–23, 26–27, 36–37, 40–41, 44–45, 52, 86, 89
Cardiac perfusion, 5
CBF-SPECT, 5, 6
Cerebral blood flow, 5
Child abuse, 6
Clinical target volume (CTV), 204, 205, 208, 210

¹¹C-methionine, 145

Coronary calcifications, 136

Crohn's disease and colitis ulcerosa, 170

D

Diabetic foot, 168, 169
[¹¹¹In]-Diethylene triamine pentacetate acid [DTPA]-
octreotide, 17, 88
Dosimetry, 214–219, 221–224
Duodenogastric reflux, biliary, 6

E

Emergency, 4–7
Endocarditis, 168–170, 176
Epileptic focus, 6
External beam radiotherapy (EBRT), 214–216, 221–223

F

F16 antibody, 96
¹⁸F-DOPA, 18, 52
Fever of unknown origin, 168, 170
Fistula, 6, 7
Fusion imaging, 2

G

⁶⁸Ga-DOTA-NOC, 18
Gamma camera, 10–12
Gamma emitters, 3–6
Ganglioneuroblastomas, 52
Gastrointestinal bleeding, 188, 190–193
Glia-derived tumours, 122
Glioblastomas, 122
Glioma(s), 122, 124–127, 207–208, 216, 221, 224
Gross tumor volume (GTV), 204, 207

H

Head trauma, 5, 7
 Hepatobiliary scintigraphy, 3, 6, 7
 Hurthle cell thyroid cancer, 70
 Hybrid machines, 2, 7
 Hyperparathyroidism (HPT), 144–148

I

¹²³I- α -methyl-tyrosine, 208
¹³¹I-anti-CD20 rituximab, 215
¹³¹I-F16, 97, 103
¹³¹I-L19SIP, 96–98, 100, 101, 215
 Image-guided radiotherapy, 204
¹²³I-MIBG, 18, 52, 56, 58, 62, 64
¹¹¹In-biotin, 182–184
¹¹¹In-Capromab pendetide, 80
 Infected joint and vascular prosthesis, 168
 Infection imaging, 167–184
 Inflammation, 168–170, 175
 Inflammatory bowel disease(s), 168, 170
¹¹¹In-oxine, 168–170
¹¹¹In-oxine-labelled WBCs, 168, 169
 Intraoperative gamma probe, 152
 Iodine, 52, 65–70, 96, 97
 I-124 PET/CT, 70

K

^{81m}Kr, 196, 197, 199–202
 Krypton, 196

L

L19 antibody, 96
 Leakage, and fistula, 6, 7
 Liver cancer, 217
 Lung cancer, 221
 Lung infections, 168
 Lung scintigraphy, 196, 197
 Lymphoma, 215, 223
 Lymphoscintigraphy, 152–154

M

Macroaggregated albumin, 196
 MDCT angiography, 196, 197
 Meckel's diverticulum, 4, 6
 Medullary thyroid carcinoma, 52
 Melanoma, 152, 153, 155, 156
 Meningiomas, 122, 128–132
 MIBG scintigraphy, 52, 53

Microcolloids, 152
 Misalignment, 136, 141
 Multi-vessel coronary artery disease, 134, 136
 Musculoskeletal infections, 169, 170
 Myocardial abscesses, 170
 Myocardial infarct (MI), 5
 Myocardial ischemia, 136
 Myocardial perfusion and viability, 134
 Myocardial perfusion imaging (MPI), 134, 136–140
 Myocardial scintigraphy (MS), 5

N

Neural crest tumors, 17, 18, 52
 Neuroblastoma(s), 18, 52, 53, 216
 Neuroendocrine, 215
 Neuroendocrine tumors (NETs), 17–19, 24–25, 28–31, 38–39, 47–49, 60, 86, 88–90, 95
 Neurological infections, 168

O

Osseous metastases, 106, 107, 110–117
 Osteomyelitis, 168–170, 178, 181

P

Paragangliomas, 18, 52, 61–62
 Parathyroid adenoma, 144–146, 148
 Parathyroid gland, 144, 147
 Parathyroid hormone (PTH), 144
 Perfusion lung scintigraphy (PLS), 5
 Pheochromocytomas, 18, 52, 53, 59–64
 Poly-traumatized, 6
 Postoperative abscesses, 168
 Primary hyperparathyroidism (pHPT), 144
 ProstaScint, 80–85
 Prostate cancer, 36, 37, 80, 81, 83, 153, 208, 210, 221
 Pulmonary embolism, 5, 7
 Pulmonary hypertension, 196

R

Radiation dose, 134, 138, 139
 Radioimmunotherapy, 80, 96, 100–103
 Radioiodine, 65–70, 75, 78
 Radioiodine ablation, 66, 69
 Radiolabeled red blood cell, 6
 Radiolabelled white blood cell scintigraphy, 168
 Radionuclide therapies, 18, 52
 Rheumatoid arthritis, 6

S

Sacroileitis, 6
 Sentinel lymph node biopsy (SLNB), 152
 Sepsis, 7
 Skeletal metastases, 218
¹⁵³Sm-EDTMP, 215, 218
 Somatostatine-receptor blockers, 17
 Somatostatine receptor scintigraphy (SRS), 17–19, 33, 39
 Somatostatin receptors, 17, 39, 41, 42, 86, 90, 122, 124, 125, 128, 130
 SPECT/CT device, 9–13
 Spine infection, 182
 Sympathetic nervous system, 52

T

Targeted radionuclide therapy, 214–219
^{99m}Tc-HMPAO, 168–170, 172–181
^{99m}Tc-MAA, 196, 197, 199–202, 217, 218
^{99m}Tc-octreotide, 86, 88

^{99m}Tc-polyphosphonates, 106, 107
^{99m}Tc-SestaMIBI, 207–209
^{99m}Tc-sesta-mibi SPECT, 144
 Technegas, 196, 197
 Tendinitis, 6
 Thyroid carcinoma (cancer), 17, 18, 52, 65, 66, 75, 78, 79, 215
 Trauma, 5–7
 Treatment planning, 204, 205, 207, 208
 TSH stimulation, 65, 66
 Tumors, 214–219, 221, 223

V

Vascular graft infection, 170

Y

⁹⁰Y and ¹⁷⁷Lu-peptides, 215, 218
⁹⁰Y-DOTATOC, 122, 125, 127, 131, 132
⁹⁰Y-ibritumomab tiuxetan, 215